Wall Street analysts expect Zafgen Inc (NASDAQ:ZFGN) to post ($0.29) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Zafgen’s earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.22). Zafgen reported earnings of ($0.41) per share during the same quarter last year, which would indicate a positive year over year growth rate of 29.3%. The business is expected to issue its next earnings report on Wednesday, November 6th.
According to Zacks, analysts expect that Zafgen will report full year earnings of ($1.23) per share for the current financial year, with EPS estimates ranging from ($1.39) to ($1.08). For the next fiscal year, analysts expect that the firm will report earnings of ($1.13) per share, with EPS estimates ranging from ($1.63) to ($0.80). Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Zafgen.
Zafgen (NASDAQ:ZFGN) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.06.
Several equities analysts recently commented on ZFGN shares. Zacks Investment Research downgraded shares of Zafgen from a “buy” rating to a “hold” rating in a research note on Saturday, July 20th. Cowen reissued a “hold” rating on shares of Zafgen in a research note on Thursday, May 30th. ValuEngine raised shares of Zafgen from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Roth Capital started coverage on shares of Zafgen in a research note on Friday, April 26th. They issued a “buy” rating and a $8.00 price objective for the company. Finally, Piper Jaffray Companies dropped their price objective on shares of Zafgen from $6.00 to $5.00 and set a “hold” rating for the company in a research note on Thursday, May 30th. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Zafgen has a consensus rating of “Hold” and a consensus price target of $7.00.
NASDAQ:ZFGN traded down $0.02 on Monday, hitting $0.83. The company had a trading volume of 139,500 shares, compared to its average volume of 354,945. The stock has a market capitalization of $32.89 million, a price-to-earnings ratio of -0.44 and a beta of -0.46. The company has a current ratio of 6.98, a quick ratio of 7.83 and a debt-to-equity ratio of 0.25. The firm has a 50 day moving average of $1.07 and a two-hundred day moving average of $2.50. Zafgen has a 52 week low of $0.83 and a 52 week high of $12.35.
Several institutional investors and hedge funds have recently bought and sold shares of ZFGN. Acadian Asset Management LLC acquired a new stake in Zafgen in the first quarter worth $389,000. Bank of New York Mellon Corp grew its holdings in Zafgen by 3.0% in the fourth quarter. Bank of New York Mellon Corp now owns 161,552 shares of the biopharmaceutical company’s stock worth $800,000 after purchasing an additional 4,699 shares during the period. Hikari Power Ltd grew its holdings in Zafgen by 16.2% in the first quarter. Hikari Power Ltd now owns 150,521 shares of the biopharmaceutical company’s stock worth $412,000 after purchasing an additional 21,000 shares during the period. Spark Investment Management LLC grew its holdings in Zafgen by 8.6% in the first quarter. Spark Investment Management LLC now owns 122,400 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 9,700 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Zafgen by 2.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 904,194 shares of the biopharmaceutical company’s stock worth $4,476,000 after purchasing an additional 21,423 shares during the period. Institutional investors own 82.89% of the company’s stock.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.